Floatz logo

mk-6240

ALS - Amyotrophic Lateral Sclerosis

Universitaire Ziekenhuizen KU LeuvenN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the ALS - Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Riluzole
AB Science
Phase 4BB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

mk-6240 is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
65 / 100
View asset →
Down syndromeDormant
B
Indicative ·
60 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →